BioSpace News Archive

Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA ® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab TM , today announced that it has commenced an underwritten public offering 5,000,000 shares of its common stock. In connection with this offering, Humanigen expects to grant the underwriters a 30-day option

Sonnet BioTherapeutics Holdings, Inc. , a biopharmaceutical company developing innovative targeted biologic drugs, announced today a business update on its ongoing programs.

Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells in the field of immuno-oncology, today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”) relating to an At-

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the fourth quarter and year ended December 30, 2020 and provided key business updates.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the first patient has been enrolled in its Phase 2 proof-of-concept study of etripamil nasal spray for the Reduction of Ventricular Rate in patients experiencing Atrial fibrillation

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a clinical and corporate update.

Armonica Technologies, Inc. announced that the company has been awarded an SBIR grant from the NIH’s National Human Genome Research Institute for “Single molecule DNA/RNA transport and Raman scattering readout in a coupled nanochannel/nanopore sequencing system.” The award of $350K is in support of the company’s single molecule sequencing technology aimed at long read sequencing of large DNA molecules.

HOYA Corporation (TSE:7741, “HOYA”) today confirms that the five year contract announced on July 6, 2020 for technical collaboration and supply of diagnostics ultrasound systems and ultrasound sensor with Hitachi, will become effective as of March 31st of 2021.

Horizon Therapeutics (Nasdaq: HZNP) and the Cubs today announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, which will include an innovative, citywide science camp and fair that allows Chicagoland-area middle and high school students to explore the connection between science and baseball as well as showcase their STEAM talents